Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas

Federica Guffanti, Ilaria Mengoli, Francesca Ricci, Ludovica Perotti, Elena Capellini, Laura Sala, Simone Canesi, Chu-Chiao Wu, Robert Fruscio, Maya Ridinger, Giovanna Damia, Michela Chiappa

Open source

DOI: 10.3390/ijms26125708
Published: 2025-06-14
Container: International Journal of Molecular Sciences
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/ijms26125708,
  title = {Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas},
  author = {Federica Guffanti and Ilaria Mengoli and Francesca Ricci and Ludovica Perotti and Elena Capellini and Laura Sala and Simone Canesi and Chu-Chiao Wu and Robert Fruscio and Maya Ridinger and Giovanna Damia and Michela Chiappa},
  year = {2025},
  journal = {International Journal of Molecular Sciences},
  doi = {10.3390/ijms26125708},
  url = {https://doi.org/10.3390/ijms26125708}
}

RIS

TY  - JOUR
TI  - Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas
AU  - Federica Guffanti
AU  - Ilaria Mengoli
AU  - Francesca Ricci
AU  - Ludovica Perotti
AU  - Elena Capellini
AU  - Laura Sala
AU  - Simone Canesi
AU  - Chu-Chiao Wu
AU  - Robert Fruscio
AU  - Maya Ridinger
AU  - Giovanna Damia
AU  - Michela Chiappa
PY  - 2025
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms26125708
UR  - https://doi.org/10.3390/ijms26125708
ER  -

APA

Guffanti, F., Mengoli, I., Ricci, F., Perotti, L., Capellini, E., Sala, L., Canesi, S., Wu, C., Fruscio, R., Ridinger, M., Damia, G., & Chiappa, M. (2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125708

Source records

crossref · retrieved 2026-09-25T01:01:29.514Z